125 related articles for article (PubMed ID: 29857071)
1. Melanoma-Derived Soluble DC-HIL/GPNMB Promotes Metastasis by Excluding T-Lymphocytes from the Pre-Metastatic Niches.
Ramani V; Teshima T; Tamura K; Chung JS; Kobayashi M; Cruz PD; Ariizumi K
J Invest Dermatol; 2018 Nov; 138(11):2443-2451. PubMed ID: 29857071
[TBL] [Abstract][Full Text] [Related]
2. Soluble DC-HIL/Gpnmb Modulates T-Lymphocyte Extravasation to Inflamed Skin.
Ramani V; Chung JS; Ariizumi K; Cruz PD
J Invest Dermatol; 2022 May; 142(5):1372-1380.e5. PubMed ID: 34695414
[TBL] [Abstract][Full Text] [Related]
3. DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors.
Chung JS; Ramani V; Kobayashi M; Fattah F; Popat V; Zhang S; Cruz PD; Gerber DE; Ariizumi K
Clin Cancer Res; 2020 Mar; 26(6):1449-1459. PubMed ID: 31822499
[TBL] [Abstract][Full Text] [Related]
4. DC-HIL/glycoprotein Nmb promotes growth of melanoma in mice by inhibiting the activation of tumor-reactive T cells.
Tomihari M; Chung JS; Akiyoshi H; Cruz PD; Ariizumi K
Cancer Res; 2010 Jul; 70(14):5778-87. PubMed ID: 20570888
[TBL] [Abstract][Full Text] [Related]
5. DC-HIL-expressing myelomonocytic cells are critical promoters of melanoma growth.
Chung JS; Tamura K; Cruz PD; Ariizumi K
J Invest Dermatol; 2014 Nov; 134(11):2784-2794. PubMed ID: 24936834
[TBL] [Abstract][Full Text] [Related]
6. Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the
Kobayashi M; Chung JS; Beg M; Arriaga Y; Verma U; Courtney K; Mansour J; Haley B; Khan S; Horiuchi Y; Ramani V; Harker D; Gopal P; Araghizadeh F; Cruz PD; Ariizumi K
Clin Cancer Res; 2019 Jan; 25(2):828-838. PubMed ID: 30049749
[TBL] [Abstract][Full Text] [Related]
7. Syndecan-4 mediates the coinhibitory function of DC-HIL on T cell activation.
Chung JS; Dougherty I; Cruz PD; Ariizumi K
J Immunol; 2007 Nov; 179(9):5778-84. PubMed ID: 17947650
[TBL] [Abstract][Full Text] [Related]
8. DC-HIL is a negative regulator of T lymphocyte activation.
Chung JS; Sato K; Dougherty II; Cruz PD; Ariizumi K
Blood; 2007 May; 109(10):4320-7. PubMed ID: 17284525
[TBL] [Abstract][Full Text] [Related]
9. Myeloid cells' evasion of melanoma immunity.
Wang J; Chen L
J Invest Dermatol; 2014 Nov; 134(11):2675-2677. PubMed ID: 25318429
[TBL] [Abstract][Full Text] [Related]
10. IRF-8 controls melanoma progression by regulating the cross talk between cancer and immune cells within the tumor microenvironment.
Mattei F; Schiavoni G; Sestili P; Spadaro F; Fragale A; Sistigu A; Lucarini V; Spada M; Sanchez M; Scala S; Battistini A; Belardelli F; Gabriele L
Neoplasia; 2012 Dec; 14(12):1223-35. PubMed ID: 23308054
[TBL] [Abstract][Full Text] [Related]
11. Molecular cloning of a dendritic cell-associated transmembrane protein, DC-HIL, that promotes RGD-dependent adhesion of endothelial cells through recognition of heparan sulfate proteoglycans.
Shikano S; Bonkobara M; Zukas PK; Ariizumi K
J Biol Chem; 2001 Mar; 276(11):8125-34. PubMed ID: 11114299
[TBL] [Abstract][Full Text] [Related]
12. Human melanoma cells inhibit the earliest differentiation steps of human Langerhans cell precursors but failed to affect the functional maturation of epidermal Langerhans cells.
Berthier-Vergnes O; Gaucherand M; Péguet-Navarro J; Plouet J; Pageaux JF; Schmitt D; Staquet MJ
Br J Cancer; 2001 Dec; 85(12):1944-51. PubMed ID: 11747338
[TBL] [Abstract][Full Text] [Related]
13. The metastatic microenvironment: Brain-derived soluble factors alter the malignant phenotype of cutaneous and brain-metastasizing melanoma cells.
Klein A; Sagi-Assif O; Izraely S; Meshel T; Pasmanik-Chor M; Nahmias C; Couraud PO; Erez N; Hoon DS; Witz IP
Int J Cancer; 2012 Dec; 131(11):2509-18. PubMed ID: 22447293
[TBL] [Abstract][Full Text] [Related]
14. Autolymphocyte therapy. II. Dependence of in vivo anti-tumor specificity and long-term immunity against murine melanoma and carcinoma on ex vivo activated donor memory T-cells.
Gold JE; Osband ME
Clin Immunol Immunopathol; 1994 Jun; 71(3):325-32. PubMed ID: 7911078
[TBL] [Abstract][Full Text] [Related]
15. Depleting syndecan-4+ T lymphocytes using toxin-bearing dendritic cell-associated heparan sulfate proteoglycan-dependent integrin ligand: a new opportunity for treating activated T cell-driven disease.
Akiyoshi H; Chung JS; Tomihari M; Cruz PD; Ariizumi K
J Immunol; 2010 Apr; 184(7):3554-61. PubMed ID: 20176742
[TBL] [Abstract][Full Text] [Related]
16. Innate and adoptive immune cells contribute to natural resistance to systemic metastasis of B16 melanoma.
Umeshappa CS; Zhu Y; Bhanumathy KK; Omabe M; Chibbar R; Xiang J
Cancer Biother Radiopharm; 2015 Mar; 30(2):72-8. PubMed ID: 25714591
[TBL] [Abstract][Full Text] [Related]
17. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
18. Intravenous administration of bone marrow-derived multipotent mesenchymal stromal cells enhances the recruitment of CD11b(+) myeloid cells to the lungs and facilitates B16-F10 melanoma colonization.
Souza LE; Almeida DC; Yaochite JN; Covas DT; Fontes AM
Exp Cell Res; 2016 Jul; 345(2):141-9. PubMed ID: 26027946
[TBL] [Abstract][Full Text] [Related]
19. VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation.
Huang H; Langenkamp E; Georganaki M; Loskog A; Fuchs PF; Dieterich LC; Kreuger J; Dimberg A
FASEB J; 2015 Jan; 29(1):227-38. PubMed ID: 25361735
[TBL] [Abstract][Full Text] [Related]
20. CYP4A in tumor-associated macrophages promotes pre-metastatic niche formation and metastasis.
Chen XW; Yu TJ; Zhang J; Li Y; Chen HL; Yang GF; Yu W; Liu YZ; Liu XX; Duan CF; Tang HL; Qiu M; Wang CL; Zheng H; Yue J; Guo AM; Yang J
Oncogene; 2017 Aug; 36(35):5045-5057. PubMed ID: 28481877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
